Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

M.D. Anderson Cancer Center

Status: Enrolling

Conditions: Mesonephric-like Adenocarcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT06377527

2023-0945

NCI-2024-03342 (Other Identifier)

Details and patient eligibility

About

To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Full description

Primary Objectives

1. To collect, both prospectively and retrospectively, data on participants characteristics, disease characterization, pathology and molecular data, treatment, and outcomes for participants with gynecologic mesonephric-like adenocarcinoma (MLA).

Secondary Objectives

1. To organize clinical information to support multifaceted queries of participant characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with participant outcome.
2. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA).
2. Patients can also be diagnosed with mesonephric adenocarcinoma (MA) or patients with mesonephric and mesonephric-like carcinosarcomas.
3. Patients who are receiving or have received treatment at any facility, including but not limited to MD Anderson Cancer Center are eligible.
4. Patients may be residents of any country and be of any ethnic background.
5. Patients who request to participate in the registry, regardless of the method by which they learned of it, are eligible to participate.
6. Patients who do not speak English can be eligible if accompanied by an institutional interpreter.

Exclusion criteria

1. Patients with other subtypes of EACs.

Trial design

2,000 participants in 1 patient group

Mesonephric-like Adenocarcinoma (MLA)

Description:

Particpants who agree to take part in this research, information such as your demographics (including your name, date of birth, race, etc.), medical history, surgical history, family history, social history, cancer diagnosis, primary treatment, and follow up will be collected. Participants also have the option to agree to the use of your previously collected tumor tissue samples for future research to better understand MLA.